Updates and Events
Iguratimod as an Alternative Therapy for Resistant Lupus Nephritis

April 1, 2020 An investigational treatment, iguratimod showed positive results in an early clinical study of people with lupus nephritis that is refractory, meaning it has stubbornly resisted previous treatment with at least two immunosuppressants. Results were reported in Arthritis Research & Therapy. The small study included 14 patients with refractory lupus nephritis. Each were […] READ MORE

The U.S. Department of Health and Human Services Accepts Donations of Hydroxychloroquine as Possible Treatments for COVID-19 Patients

March 31, 2020 A statement issued March 29 by the U.S. Department of Health and Human Services (HHS) announced that millions of donated doses of hydroxychloroquine sulfate and chloroquine phosphate had been accepted into the Strategic National Stockpile. In addition, the statement announced that the Food and Drug Administration has granted Emergency Use Authorization (EUA) […] READ MORE

DECLARACIÓN DEL 26 DE MARZO: La Alianza para la investigación de Lupus pone en perspectiva la escasez de Plaquenil (hidroxicloroquina) para la comunidad con lupus

26 de marzo de 2020 La Alianza para la investigación de Lupus (LRA), la principal organización de investigación del mundo dedicada a la investigación del lupus, continúa observando rápidamente los cambios en relación con la COVID-19 y está controlando de cerca las políticas y acciones del gobierno federal, las agencias de atención médica, las organizaciones […] READ MORE

MARCH 26 STATEMENT: Lupus Research Alliance Puts Plaquenil (Hydroxychloroquine) Shortage into Perspective for Lupus Community

March 26, 2020 The Lupus Research Alliance (LRA), the world’s leading research organization dedicated to lupus research, continues to watch rapidly changing developments regarding COVID-19 and is closely monitoring the policies and actions of the federal government, healthcare agencies, medical organizations and the pharmaceutical industry on behalf of people with lupus. Thrust into the spotlight […] READ MORE

CVS Preserving Plaquenil Supply for Patients Taking It

March 26, 2020 CVS put out the following statement yesterday assuring its clients that the company is protecting a supply for people already taking hydroxychloroquine. CVS Health helping protect supply of medicines potentially useful for COVID-19 treatment CVS Caremark, the pharmacy benefit management business of CVS Health, is working with clients to implement new measures […] READ MORE

LRA Sponsors COVID-19 Global Rheumatology Alliance

March 25, 2020 LRA Sponsors COVID-19 Global Rheumatology Alliance The LRA is proud to be among the sponsors of the COVID-19 Global Rheumatology Alliance, a grassroots group led by rheumatologists and uniting rheumatologists and patients with rheumatic diseases worldwide to respond to the global pandemic. In concert with the American College of Rheumatology, the group’s […] READ MORE

Hydroxychloroquine: Common Lupus Drug in Testing for COVID-19

March 19, 2020 In December 2019, a new virus called SARS-COV-2 was identified in Wuhan, China. This virus was found to cause a severe respiratory illness in patients which was later named after the type of virus that caused it and the year it was identified (coronavirus disease 2019 or COVID-19)1 Currently there is no […] READ MORE

Actualización sobre COVID-19: un mensaje del presidente y director ejecutivo de la LRA

18 de marzo de 2020 Estimados amigos: Su bienestar es la máxima prioridad para todos nosotros en la Alianza para la investigación de Lupus (Lupus Research Alliance, LRA). Estamos consultando a los mejores clínicos y científicos especializados en lupus para supervisar la situación planteada por la propagación del coronavirus SARS (SARS-CoV-2), comúnmente denominado COVID-19, en […] READ MORE

Together, ManyOne Can make a difference!